Natural killer cell receptor (NKR) (NKR)

Natural killer (NK) cell receptors and related lymphocyte receptors are a heterogeneous group of cell-surface proteins that govern the activation, inhibition, and overall effector functions of the immune system (PubMed: 28553955). These receptors are broadly categorized into activating receptors, such as NKG2D and Natural Cytotoxicity Receptors (NKp30, NKp44, NKp46), and inhibitory receptors, including Killer cell Immunoglobulin-like Receptors (KIRs) and NKG2A (NIH: PMC4408281). Their fundamental biological role is to distinguish between healthy "self" cells and abnormal cells—such as those infected by viruses or undergoing malignant transformation—by recognizing ligands like MHC class I molecules or stress-induced proteins (UniProt: P43626). In the context of disease, dysregulation of these receptors can lead to immune evasion by tumors or the development of chronic infections and autoimmune disorders (StatPearls: NBK537181). Therapeutically, these receptors are major targets for cancer immunotherapy; monoclonal antibodies like monalizumab (targeting NKG2A) and lirilumab (targeting KIR) are designed to block inhibitory signals, thereby enhancing the natural ability of NK cells and T cells to destroy cancer cells (PubMed: 30559424). Additionally, bispecific and trispecific "NK cell engagers" are being developed to bridge NK receptors directly to tumor-associated antigens, providing a potent mechanism for targeted cell lysis. Because this target entry represents a broad class of receptors rather than a single molecular entity, therapeutic applications vary significantly depending on the specific receptor-ligand pair being addressed.

Other names

Immune cell receptors on natural killer cells and other lymphocytesNK cell receptorLymphocyte receptorKiller cell immunoglobulin-like receptorNatural cytotoxicity receptorActivating and inhibitory immune receptor

Modulation of immune cell activation through the blockade of inhibitory signaling pathways (checkpoint inhibition) or the stimulation of activating receptors to enhance cytotoxicity against target cells.